In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently ...

In The Lancet Respiratory Medicine, Olivier Sitbon and colleagues1 present the results of a randomised, phase 2b clinical trial (ELEVATE-2) that compared the safety and efficacy of pulmonary arterial ...

As more drugs approach late-stage development for PAH, Cereno Scientific’s CEO expects more successful disease-modifying ...

In a recent study published in The Journal of Neuroscience, researchers at the University of Alabama at Birmingham uncovered ...

Peptides have become increasingly prominent in the field of research due to their potential to modulate various biological ...

The European approval comes months after the FDA’s approval of the first-of-its-kind treatment for pulmonary arterial ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and ...

About Cibotercept Cibotercept is designed to bind to and inhibit the signaling of TGF-β ligands that stimulate smooth muscle hypertrophy and fibrosis, including activin A, activin B and myostatin.

Keros Therapeutics Inc. has presented preclinical data on the activin receptor type IIB ligand trap RKER-012 (a research version of KER-012 [cibotercept]) in a preclinical pulmonary arterial ...